Objective To assess patient- and clinician-reported outcomes, efficacy, and safety of tirbanibulin 1% administered to patients with actinic keratoses (AKs) in Spain and Italy. Methods TIRBASKIN is a multicenter, single-cohort, phase IV, low-interventional clinical study […]
To assess the real-life efficacy and safety of varenicline in a hospital-based smoking cessation program. We conducted a longitudinal prospective study including 310 smokers treated with varenicline at our hospital’s Smoking Cessation Unit between 2011 […]
Background The safety and efficacy profile of dupilumab in the management of atopic dermatitis (AD) are established in clinical trials. However, long-term real-world persistence data in Spain are limited. Objective The primary endpoint of the […]
Background Bimekizumab is the first and only dual selective inhibitor of IL-17 A and IL-17 F that has been proven effective and safe in Phase 3 clinical trials and has been approved by the European […]
Background Randomized clinical trials (RCTs) supporting advanced treatments for atopic dermatitis (AD) involve highly selected patients, limiting their generalizability. Objective To determine the proportion of adults on advanced systemic therapy for AD in clinical practice […]
Introduction Despite existing guidelines, many patients with asthma do not achieve adequate control of their disease. This is largely due to low adherence to inhaled therapy. Single-inhaler administration may improve this and other aspects of […]
The objective of this article is to collect and describe the most relevant BIOBADADERM findings since its beginning in 2008. BIOBADADERM is a prospective cohort registry whose main aim is to analyze the safety profile […]
JAK inhibitors target specific inflammatory cytokines involved in various inflammatory diseases. Four molecules have been approved for dermatological use: upadacitinib, baricitinib, abrocitinib and topical ruxolitinib. Off-label prescriptions for other dermatological conditions have been reported. We […]
Background Hypertension has high global prevalence with suboptimal control rates. In Lebanon, its prevalence is estimated to around 37%. Antihypertensive monotherapy proved to have limited effectiveness in reducing blood pressure. A commonly used combination of […]